Compared with usual care, GLP-1 receptor agonists tirzepatide and semaglutide may be cost-effective options for patients with ...

GLP-1 RA tirzepatide may be more cost-effective for patients with obesity and knee osteoarthritis than semaglutide.

CAR-T therapy's cost per QALY is approximately $100,000, with consistent results across PSM, STM, and DES models. DES uniquely incorporates wait time, significantly affecting CAR-T's ...

A hypothetical cohort of women, assumed to be initially free of osteoporosis-related bone fractures, is followed on an annual basis for 25 years. Women in the cohort face risks for three important ...

A Markov chain model evaluated the cost-effectiveness of abemaciclib and ribociclib with letrozole compared with letrozole alone for HR+/HER2– EBC from a payer perspective in India. Key measures ...

A joint model combining decision tree with partitioned survival models was developed. A two-round consensus panel was performed to describe clinical practice of Spanish reference centers, providing ...

A microsimulation model was used to evaluate the cost-effectiveness of two glucagon-like peptide-1 receptor agonists (GLP1RAs), semaglutide and tirzepatide, for patients with osteoarthritis and ...

Relative to a policy of no treatment, tibolone 2.5 mg/day was found to be an economically attractive treatment modality in Sweden for postmenopausal women who face a high risk of osteoporotic ...

A microsimulation model was used to evaluate the cost-effectiveness of two glucagon-like peptide-1 receptor agonists (GLP1RAs), semaglutide and tirzepatide, for patients with osteoarthritis and ...